# US 2026/0265747 A1 · Oligonucleotides for htt-1a modulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265747 A1
- Document ID: US20260265747A1
- Status: Published application
- Kind: A1
- Application number: 19/454,946
- Filed: 2026-01-21
- Published: 2026-09-10
- Earliest claimed: 2020-08-03
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Anastasia Khvorova; Julia Alterman; Socheata Ly; Faith Conroy; Daniel O'Reilly
- Web page: https://patentgrep.com/patent/US20260265747A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/86: Viral vectors
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/351: Conjugate
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2310/3533: Halogen
- C12N 2310/52: branched
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2320/30: Special therapeutic applications
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2750/14142: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to novel HTT-1A targeting sequences. Novel HTT-1A targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim 3

A double stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, each strand with a 5′ end and a 3′ end, wherein:
the sense strand is 15 nucleotides to 20 nucleotides in length and the antisense strand is 20 nucleotides to 25 nucleotides in length,
the antisense strand comprises a sequence complementary to a huntingtin variant 1A (HTT-1A) nucleic acid sequence of SEQ ID NO: 544 or 545, and
the antisense strand comprises at least 50% 2′-O-methyl nucleotide modifications.

### Claim 4

(canceled)

### Claim 5 (depends on 3)

The dsRNA molecule of claim 3, wherein the antisense strand comprises a nucleic acid sequence complementary to a HTT-1A nucleic acid sequence of SEQ ID NO: 592 or 593.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The dsRNA molecule of claim 5, wherein the antisense strand comprises full complementarity to the HTT-1A nucleic acid sequence of SEQ ID NO: 592 or 593.

### Claim at position 7

8-9. (canceled)

### Claim 10 (depends on 3)

The dsRNA molecule of claim 3, wherein the antisense strand is 20, 21, or 22 nucleotides in length.

### Claim at position 9

11-12. (canceled)

### Claim 13 (depends on 3)

The dsRNA molecule of claim 3, wherein the sense strand is 16, 18, or 20 nucleotides in length.

### Claim at position 11

14-16. (canceled)

### Claim 17 (depends on 3)

The dsRNA molecule of claim 3, comprising a double-stranded region of 15 base pairs to 20 base pairs.

### Claim at position 13

18-21. (canceled)

### Claim 22 (depends on 3)

The dsRNA molecule of claim 3, wherein the dsRNA molecule further comprises a blunt-end.

### Claim 23 (depends on 3)

The dsRNA molecule of claim 3, wherein the dsRNA molecule further comprises at least one single stranded nucleotide overhang.

### Claim at position 16

24-27. (canceled)

### Claim 28 (depends on 3)

The dsRNA molecule of claim 3, further comprising at least one modified nucleotide selected from the group consisting of a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, and a mixture thereof.

### Claim 29

(canceled)

### Claim 30 (depends on 3)

The dsRNA molecule of claim 3, wherein dsRNA molecule further comprises at least one modified internucleotide linkage.

### Claim at position 20

31-33. (canceled)

### Claim 34 (depends on 30)

The dsRNA molecule of claim 30, wherein the at least one modified internucleotide linkage has the structure of Formula I:
wherein:
B is a base pairing moiety;
W is selected from the group consisting of O, OCH2, OCH, CH2, and CH;
X is selected from the group consisting of a halo, hydroxy, and a C1-6 alkoxy;
Y is selected from the group consisting of O−, OH, OR, NH−, NH2, S−, and SH;
Z is selected from the group consisting of O and CH2;
R is a protecting group; and
is an optional double bond.

### Claim 35 (depends on 3)

The dsRNA molecule of claim 3, wherein the dsRNA comprises at least 80% chemically modified nucleotides or is fully chemically modified.

### Claim at position 23

36-37. (canceled)

### Claim 38 (depends on 3)

The dsRNA molecule of claim 3, wherein the antisense strand comprises at least 70% 2′-O-methyl nucleotide modifications and/or the sense strand comprises at least 65% 2′-O-methyl nucleotide modifications.

### Claim at position 25

39-44. (canceled)

### Claim 45 (depends on 3)

The dsRNA molecule of claim 3, wherein the antisense strand further comprises a 5′ phosphate, a 5′-alkyl phosphonate, a 5′ alkylene phosphonate, or a 5′ alkenyl phosphonate.

### Claim 46

(canceled)

### Claim 47 (depends on 3)

The dsRNA molecule of claim 3, wherein:
(1) the antisense strand comprises a region of alternating 2′-methoxy-ribonucleotides and 2′-fluoro-ribonucleotides;
(2) the nucleotides at positions 2 and 14 from the 5′ end of the antisense strand are not 2′-methoxy-ribonucleotides;
(3) the nucleotides at positions 1 through 7 from the 3′ end of the antisense strand are connected to each other via phosphorothioate internucleotide linkages;
(4) the sense strand comprises a region of alternating 2′-methoxy-ribonucleotides and 2′-fluoro-ribonucleotides; and
(5) the nucleotides at positions 1-2 from the 5′ end of the sense strand are connected to each other via phosphorothioate internucleotide linkages.

### Claim 48 (depends on 3)

The dsRNA molecule of claim 3, wherein:
A:
(1) the antisense strand comprises at least 70% 2′-O-methyl modifications;
(2) the nucleotide at position 14 from the 5′ end of the antisense strand is not a 2′-methoxy-ribonucleotide;
(3) the nucleotides at positions 1 through 7 from the 3′ end of the antisense strand are connected to each other via phosphorothioate internucleotide linkages;
(4) the sense strand comprises at least 70% 2′-O-methyl modifications; and
(5) the nucleotides at positions 1-2 from the 5′ end of the sense strand are connected to each other via phosphorothioate internucleotide linkages;
B:
(1) the antisense strand comprises at least 85% 2′-O-methyl modifications;
(2) the nucleotides at positions 2 and 14 from the 5′ end of the antisense strand are not 2′-methoxy-ribonucleotides;
(3) the nucleotides at positions 1 through 7 from the 3′ end of the antisense strand are connected to each other via phosphorothioate internucleotide linkages;
(4) the sense strand comprises 100% 2′-O-methyl modifications; and
(5) the nucleotides at positions 1-2 from the 5′ end of the sense strand are connected to each other via phosphorothioate internucleotide linkages;
C:
(1) the antisense strand comprises at least 75% 2′-O-methyl modifications;
(2) the nucleotides at position 14 from the 5′ end of the antisense strand is not a 2′-methoxy-ribonucleotide;
(3) the nucleotides at positions 1 through 7 from the 3′ end of the antisense strand are connected to each other via phosphorothioate internucleotide linkages;
(4) the sense strand comprises 100% 2′-O-methyl modifications; and
(5) the nucleotides at positions 1-2 from the 5′ end of the sense strand are connected to each other via phosphorothioate internucleotide linkages;
D:
(1) the antisense strand comprises at least 75% 2′-O-methyl modifications;
(2) the nucleotides at positions 2, 4, 5, 6, and 14 from the 5′ end of the antisense strand are not 2′-methoxy-ribonucleotides;
(3) the nucleotides at positions 1 through 7 from the 3′ end of the antisense strand are connected to each other via phosphorothioate internucleotide linkages;
(4) the sense strand comprises 100% 2′-O-methyl modifications; and
(5) the nucleotides at positions 1-2 from the 5′ end of the sense strand are connected to each other via phosphorothioate internucleotide linkages;
E:
(1) the antisense strand comprises at least 75% 2′-O-methyl modifications;
(2) the nucleotides at positions 2, 14, and 16 from the 5′ end of the antisense strand are not 2′-methoxy-ribonucleotides;
(3) the nucleotides at positions 1 through 7 from the 3′ end of the antisense strand are connected to each other via phosphorothioate internucleotide linkages;
(4) the sense strand comprises at least 65% 2′-O-methyl modifications;
(5) the nucleotides at positions 7, 9, 10, and 11 from the 3′ end of the sense strand are not 2′-methoxy-ribonucleotides; and
(6) the nucleotides at positions 1-2 from the 5′ end of the sense strand are connected to each other via phosphorothioate internucleotide linkages; or
F:
(1) the antisense strand comprises at least 75% 2′-O-methyl modifications;
(2) the nucleotides at positions 2 and 14 from the 5′ end of the antisense strand are not 2′-methoxy-ribonucleotides;
(3) the nucleotides at positions 1 through 7 from the 3′ end of the antisense strand are connected to each other via phosphorothioate internucleotide linkages;
(4) the sense strand comprises at least 75% 2′-O-methyl modifications;
(5) the nucleotides at positions 7, 10, and 11 from the 3′ end of the sense strand are not 2′-methoxy-ribonucleotides; and
(6) the nucleotides at positions 1-2 from the 5′ end of the sense strand are connected to each other via phosphorothioate internucleotide linkages.

### Claim at position 30

49-53. (canceled)

### Claim 54 (depends on 3)

The dsRNA molecule of claim 3, further comprising a functional moiety is linked to the 5′ end and/or the 3′ end of the antisense strand and/or the sense strand.

### Claim at position 32

55-56. (canceled)

### Claim 57 (depends on 54)

The dsRNA molecule of claim 54, wherein the functional moiety comprises a hydrophobic moiety selected from the group consisting of fatty acids, steroids, secosteroids, lipids, gangliosides, nucleoside analogs, endocannabinoids, vitamins, and a mixture thereof.

### Claim at position 34

58-62. (canceled)

### Claim 63 (depends on 54)

The dsRNA molecule of claim 54, wherein the functional moiety is linked to the antisense strand and/or the sense strand by a linker.

### Claim 64 (depends on 63)

The dsRNA molecule of claim 63, wherein the linker comprises a divalent or trivalent linker.

### Claim at position 37

65-68. (canceled)

### Claim 69 (depends on 3)

The dsRNA molecule of claim 3, wherein the nucleotides at positions 1 and 2 from the 3′ end of the sense strand, and the nucleotides at positions 1 and 2 from the 5′ end of the antisense strand are connected to adjacent ribonucleotides via phosphorothioate linkages.

### Claim 70 (depends on 3)

A pharmaceutical composition for inhibiting expression of a huntingtin variant 1A (HTT-1A) nucleic acid in an organism, comprising the dsRNA molecule of claim 3 and a pharmaceutically acceptable carrier.

### Claim at position 40

71-79. (canceled)

### Claim 80

A vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes a double stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, each strand with a 5′ end and a 3′ end, wherein:
the sense strand comprises 15 to 20 nucleotides in length and the antisense strand comprises 20 nucleotides to 25 nucleotides in length,
the dsRNA molecule inhibits expression of a huntingtin variant 1A (HTT-1A) nucleic acid by at least 30%, and
the antisense strand comprises a sequence comprising complementary to a HTT-1A nucleic acid sequence of SEQ ID NO: 544 or 545.

### Claim at position 42

81-85. (canceled)

### Claim 86 (depends on 80)

A recombinant adeno-associated virus (rAAV) comprising the vector of claim 80 and an AAV capsid.

### Claim at position 44

87-187. (canceled)
